These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35248718)

  • 1. Implementation of a Collaborated Antimicrobial Stewardship Program and Outpatient Parenteral Antimicrobial Therapy (OPAT) Unit-driven Monoclonal Antibody Therapy Program for COVID-19 at an NYC Hospital.
    Rodriguez GD; Wu Y; Karnik K; Ruddy S; Kula A; Warren N; Yashayev R; Sajid F; Prasad N; Yoon J; Turett G; Yung L; Urban C; Lee CH; Abraham J; Cooke JT; Sharma M; Jaffer A; Segal-Maurer S
    Int J Infect Dis; 2022 May; 118():214-219. PubMed ID: 35248718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
    Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
    Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
    McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
    JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of an outpatient parenteral antimicrobial treatment (OPAT) as part of a paediatric-specific PROA program.
    Fernández-Polo A; Ramon-Cortes S; Plaja-Dorca J; Bartolomé-Comas R; Vidal-Valdivia L; Soler-Palacín P;
    Enferm Infecc Microbiol Clin (Engl Ed); 2023 Apr; 41(4):230-234. PubMed ID: 35961853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial stewardship in the outpatient parenteral antimicrobial therapy (OPAT) setting: the impact of prescription assessment by an infectious diseases specialist.
    Cassettari V; Novato N; Onuchic MHF
    Braz J Infect Dis; 2021; 25(2):101560. PubMed ID: 33716018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
    Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
    Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.
    Buonomo AR; Filippo ID; Esposito N; Saccone G; Nobile M; Viceconte G; Villari R; Carlo CD; Bifulco G; Gentile I
    Am J Perinatol; 2024 Feb; 41(3):365-367. PubMed ID: 37072016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    O'Horo J; Challener DW; Anderson RJ; Arndt RF; Ausman SE; Hall ST; Heyliger A; Kennedy BD; Sweeten PW; Ganesh R; Razonable RR
    Mayo Clin Proc; 2022 May; 97(5):943-950. PubMed ID: 35512884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the first comprehensive outpatient parenteral antimicrobial therapy program in a tertiary care hospital in Japan.
    Hase R; Yokoyama Y; Suzuki H; Uno S; Mikawa T; Suzuki D; Muranaka K; Hosokawa N
    Int J Infect Dis; 2020 Jun; 95():210-215. PubMed ID: 32205285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient parenteral antimicrobial therapy and antibiotic stewardship: opponents or teammates?
    Steffens E; Quintens C; Derdelinckx I; Peetermans WE; Van Eldere J; Spriet I; Schuermans A
    Infection; 2019 Apr; 47(2):169-181. PubMed ID: 30443780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities.
    Tulledge-Scheitel S; Bell SJ; Larsen JJ; Bierle DM; Takahashi P; Moehnke DE; Destro Borgen MJ; Springer DJ; Reinschmidt KJ; Baumbach LJ; Matoush JA; Heyliger A; Hanson SN; Razonable RR; Ganesh R
    J Am Geriatr Soc; 2021 Apr; 69(4):868-873. PubMed ID: 33619724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinician Perspectives on Monoclonal Antibody Treatment for High-Risk Outpatients with COVID-19: Implications for Implementation and Equitable Access.
    Kwan BM; Sobczak C; Beaty L; Wynia MK; DeCamp M; Owen V; Ginde AA
    J Gen Intern Med; 2022 Oct; 37(13):3426-3434. PubMed ID: 35790666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
    Ganesh R; Philpot LM; Bierle DM; Anderson RJ; Arndt LL; Arndt RF; Culbertson TL; Destro Borgen MJ; Hanson SN; Kennedy BD; Kottke BB; Larsen JJ; Ramar P; Rosedahl JK; Seville MT; Speicher LL; Tulledge-Scheitel SM; Wilker CG; Razonable RR
    J Infect Dis; 2021 Oct; 224(8):1278-1286. PubMed ID: 34279629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient parenteral antimicrobial therapy (OPAT) from an emergency model applied during the COVID-19 pandemic to standard of care: Preliminary lessons from our experience.
    Giuliano G; Raffaelli F; Faliero D; Tamburrini E; Tarantino D; Nurchis MC; Scoppettuolo G
    Infect Dis Now; 2023 Mar; 53(2):104642. PubMed ID: 36642101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities.
    Monday LM; Brar I; Alangaden G; Ramesh MS
    J Clin Pharm Ther; 2022 Sep; 47(9):1438-1443. PubMed ID: 35633095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience.
    Verderese JP; Stepanova M; Lam B; Racila A; Kolacevski A; Allen D; Hodson E; Aslani-Amoli B; Homeyer M; Stanmyre S; Stevens H; Garofalo S; Henry L; Venkatesan C; Gerber LH; Motew SJ; Jones JS; Younossi ZM
    Clin Infect Dis; 2022 Mar; 74(6):1063-1069. PubMed ID: 34166513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial stewardship and bamlanivimab: Opportunities for outpatient preauthorization?
    Patel PK; Nori P; Stevens MP
    Infect Control Hosp Epidemiol; 2021 Dec; 42(12):1524-1526. PubMed ID: 33213544
    [No Abstract]   [Full Text] [Related]  

  • 19. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telling the difference and the telling differences between hospital in the home and outpatient parenteral antibiotic therapy.
    Montalto M; Ko SQ
    Intern Med J; 2022 May; 52(5):880-884. PubMed ID: 35538016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.